Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $657.53, giving the company a market capitalization of 69.13B. It carries a P/E multiple of 15.74 and pays a dividend yield of 40.2%.
On 2025-11-09, Regeneron(REGN) stock moved within a range of $640.99 to $658.21. With shares now at $657.53, the stock is trading +2.6% above its intraday low and -0.1% below the session's peak.
Trading activity shows a volume of 658.25K, compared to an average daily volume of 1.13M.
The stock's 52-week range extends from a low of $476.49 to a high of $834.42.
The stock's 52-week range extends from a low of $476.49 to a high of $834.42.
REGN News
Regeneron Pharmaceuticals, Inc.'s ( ) stock showed strength, with investors undeterred by its weak earnings report. We think that shareholders might be missing...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from two Phase 2 clinical trials evaluating its investigational factor XI antibo...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Analyst ratings
72%
of 29 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent (dupilumab) for treating allergic fu...
(RTTNews) - Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced the presentation of positive results from the pivotal LIBERTY-AFRS-AIMS Phase 3 trial evaluating the...
Regeneron Pharmaceuticals recently reported strong third-quarter earnings and engaged in new collaborations, including a license and development agreement with...
Curious about whether Regeneron Pharmaceuticals is a bargain or overpriced right now? You are not alone, and we are about to dig deep into what makes the stock...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...
OPKO Health (OPK) recently made headlines with two key announcements: a new collaboration with Regeneron to develop antibody therapies that could be worth over...
